L
LENZ Therapeutics, Inc. (LENZ)
NMS – Real Time Price. Currency in USD
7.91
-2.08 (-20.82%)
At close: May 12, 2026, 4:00 PM EDT
8.25
+0.34 (4.30%)
Pre-market: May 13, 2026, 4:29 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
7.91
-2.08 (-20.82%)
At close: May 12, 2026, 4:00 PM EDT
8.25
+0.34 (4.30%)
Pre-market: May 13, 2026, 4:29 AM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 14.23 | 6.05 | 10 | |
| Quick ratio | 14.09 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | 19M | 19M |
| Gross Profit | -8M | -15K | -58K | 18M | 18M |
| Operating Income | -106M | -72M | -59M | -91M | -91M |
| Net Income | -101M | -70M | -50M | -82M | -82M |
| EBITDA | -97M | -72M | -59M | -91M | -91M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -97.67 | 1.0 |
| Next quarter | -40.8 | -82.76 | 1.0 |
| Current year | 30.33 | -37.8 | 5.5 |
| Next year | 202.7 | 25.03 | 10 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -87.29 | -114.94 | -96.6 | -266.26 | 1.0 |
| Y/Y | 999 | -183.71 | -152.16 | -258.32 | 3.3 |
| 3y average | 999 | -1.78 | 28.7 | 6.7 | 6.5 |
| 5y average | 999 | -10.32 | 27.75 | -102.4 | 5.5 |
| Weighted average score | 4.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $25.2M significantly exceed its total debt $815.0K, ensuring strong financial flexibility
Total current assets $301.4M exceed Total current liabilities $21.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$33.1M limits the company's ability to reinvest or pay down debt